Welcome to our dedicated page for Taro Pharmaceutical Inds news (Ticker: TARO), a resource for investors and traders seeking the latest updates and insights on Taro Pharmaceutical Inds stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Taro Pharmaceutical Inds's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Taro Pharmaceutical Inds's position in the market.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) reported its financial results for the quarter and nine months ended December 31, 2021. Net sales decreased to $139.0 million, while gross profit rose to $76.0 million, representing a margin of 54.7%. The company faced a net income drop to $26.3 million from $32.9 million. For the nine months, net sales increased to $418.1 million, but gross profit fell to $215.8 million. Legal settlements related to antitrust issues significantly impacted finances. Cash and equivalents fell to $1.3 billion due to DOJ payments and share repurchases. FDA approvals for new drug applications were also noted.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced it will release financial results for the quarter and nine months ended December 31, 2021, after market close on January 27, 2022. The financial report will be available on Taro’s official website. Taro is committed to delivering high-quality healthcare products through its extensive research and development efforts.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) has appointed William J. Coote as Vice President, Chief Financial Officer, and Chief Accounting Officer, effective immediately. Mr. Coote brings over 25 years of financial executive experience, having served as Taro's AVP, Treasurer, and Business Finance since 2008. His previous roles include positions at Bowne & Co., Prudential Realty, Merrill Lynch, and Ernst & Young.
CEO Uday Baldota expressed confidence in Coote's leadership, highlighting his track record and experience as vital for executing the company's strategy.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) reported unaudited financial results for the quarter and six months ended September 30, 2021. For the quarter, net sales were $132.0 million, down $10.9 million from the previous year, with gross profit of $62.0 million (47% of net sales) decreasing significantly. Operating income fell to $24.4 million from $40.9 million, reflecting increased tax expenses and settlements related to DOJ investigations. For the first half, net sales increased to $279.1 million, but gross profit decreased. The company continues to focus on strategic opportunities and recently received FDA approval for a new product.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) will release its financial results for the quarter and six months ended September 30, 2021, after the market closes on Thursday, October 28, 2021. The results will be accessible on Taro's official website. Taro is a multinational pharmaceutical company focused on the discovery, development, manufacturing, and marketing of high-quality healthcare products.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) reported unaudited financial results for the quarter ended June 30, 2021, showing net sales of $147.1 million, a 25.1% increase from the previous year. Gross profit was $77.7 million, but the gross margin decreased to 52.8%. Operating loss narrowed to $(19.2) million, while net loss improved to $(18.8) million. Diluted earnings per share, excluding settlements, rose to $1.09. Cash flow from operations totaled $44.0 million. The company repurchased 254,717 shares during the quarter as part of its $300 million repurchase program.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) will announce its financial results for the quarter ending June 30, 2021, on July 27, 2021, after market close. Investors can access the financial results on Taro's official website.
The company focuses on developing and marketing high-quality healthcare products to meet customer needs.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) has announced the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021. Ms. Huang is leaving to explore other opportunities. The CEO, Uday Baldota, expressed gratitude for her contributions, particularly during the COVID-19 pandemic. The company is now in the process of searching for her successor.
Taro remains committed to its mission of developing high-quality healthcare products.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) has made its Annual Report on Form 20-F for the fiscal year ending March 31, 2021, available. This report can be accessed in the Investor Relations section of Taro's website or through the SEC’s website. Hard copies can be requested free of charge. Taro continues to focus on meeting customer needs through the development and marketing of high-quality healthcare products.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) reported unaudited financial results for the quarter and year ended March 31, 2021. Net sales decreased to $148.3 million for the quarter and $549.0 million for the year, down by $26.6 million and $95.8 million, respectively. Gross profit for the quarter was $76.9 million (51.9% of net sales) compared to 58.5% the previous year. The company faced substantial settlements and loss contingencies totaling $558.9 million. Taro recorded a net loss of $(386.7) million for the year, leading to a diluted loss per share of $(10.12). Despite challenges, Taro announced new FDA approvals and launched a skincare brand, Bee Rx™.